Adimab
Adimab52About
What does Adimab do?
Adimab is a leading biotechnology company focused on the discovery and optimization of therapeutic antibodies. Their proprietary yeast-based platform enables the rapid identification of highly diverse and potent antibodies for various diseases, partnering with pharmaceutical and biotechnology companies to advance drug development.
What is Adimab's revenue?
StartupHub estimates Adimab's annual revenue at $30.3M (range $16.5M to $69.7M, 65% confidence), based on comparable companies in the sector.
What is Adimab's valuation?
StartupHub estimates Adimab's effective valuation at $415.7M (range $262.5M to $630.0M, 10% confidence), based on comparable companies in the sector.
How much funding has Adimab raised?
Adimab has raised a total of $105M in funding. The most recent round on record is Series B.
Where is Adimab headquartered?
Adimab is headquartered in Lebanon, United States.
When was Adimab founded?
Adimab was founded in 2007.
What industry does Adimab operate in?
Adimab operates in Biotech, Drug Discovery, Antibody Discovery, Therapeutic Antibodies, Biopharmaceutical, Yeast Display.
How many employees does Adimab have?
Adimab has approximately 139 people on record.
No comments yet. Be the first to share your take.